Bosutinib + Imatinib

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive

Conditions

Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive

Trial Timeline

Jul 15, 2014 → Apr 17, 2020

NCT ID

NCT02130557

About Bosutinib + Imatinib

Bosutinib + Imatinib is a phase 3 stage product being developed by Pfizer for Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive. The current trial status is completed. This product is registered under clinical trial identifier NCT02130557. Target conditions include Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02130557	Phase 3	Completed	Jul 15, 2014	Apr 17, 2020	Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive
NCT00574873	Phase 3	Completed	Feb 5, 2008	May 27, 2015	Chronic Myeloid Leukemia

Competing Products

20 competing products in Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive

See all competitors

Product	Company	Stage	Hype Score
AFM28	Affimed	Phase 1	25
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen	CSPC Pharmaceutical Group Limited	Phase 2	51
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells	CSPC Pharmaceutical Group Limited	Phase 2	51
TERN-701	Terns Pharmaceuticals	Phase 1/2	38
Fludarabine + Cyclophosphamide + PRGN-3007	Precigen	Phase 1	28
PRGN-3006 T Cells	Precigen	Phase 1	28
Bisantrene	Race Oncology	Phase 2	44
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridine	Race Oncology	Phase 1	25
Bisantrene + Fludarabine + Clofarabine	Race Oncology	Phase 2	44
ZN-d5 ZN-c3 + ZN-c3	Zentalis Pharmaceuticals	Phase 1/2	33
ZN-d5	Zentalis Pharmaceuticals	Phase 1	25
Pirtobrutinib + Venetoclax + Rituximab	Eli Lilly	Phase 3	77
Pirtobrutinib	Eli Lilly	Phase 2	52
Ibrutinib + LY3214996	Eli Lilly	Phase 1	33
Pirtobrutinib + Acalabrutinib	Eli Lilly	Phase 2	52
VIP943 (QW) + VIP943 (BIW)	Vincerx Pharma	Phase 1	25
Pirtobrutinib + Ibrutinib	Eli Lilly	Phase 3	77
LY2523355	Eli Lilly	Phase 1	33
Tomivosertib	eFFECTOR Therapeutics	Phase 1	25
gemtuzumab ozogamycin	Chugai Pharmaceutical	Phase 3	77

Other Products from Pfizer